[
    {
        "other_ids": [
            {
                "name": "Study Protocol Other Identifier",
                "value": "2018-000340-26"
            }
        ],
        "amendment_date": null,
        "keywords": null,
        "dcp_id": null,
        "interventional_model": "Parallel",
        "lead_org": "Bristol-Myers Squibb",
        "eligibility": {
            "unstructured": [
                {
                    "inclusion_indicator": true,
                    "display_order": 0,
                    "description": "Histologic or cytologic confirmation of a solid tumor that is advanced (metastatic, recurrent and/or unresectable) with measurable disease per RECIST v1.1"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 1,
                    "description": "At least 1 lesion accessible for biopsy"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 2,
                    "description": "Eastern Cooperative Oncology Group Performance Status of 0 or 1"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 3,
                    "description": "Participants with CNS metastases as the only site of active disease (Participants with controlled brain metastases; however, will be allowed to enroll)"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 4,
                    "description": "Participants with active, known or suspected autoimmune disease"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 5,
                    "description": "Participants with conditions requiring systemic treatment with either corticosteroids (> 10mg prednisone equivalents) or other immunosuppressive medications within 14 days of study treatment administration"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 6,
                    "description": "Participants with a known history of testing positive for Human Immunodeficiency Virus (HIV) or known Acquired Immunodeficiency Syndrome (AIDS)"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 7,
                    "description": "Cytotoxic agents, unless at least 4 weeks have elapsed from last dose of prior anti-cancer therapy and initiation of study therapy"
                }
            ],
            "structured": {
                "max_age": "999 Years",
                "max_age_number": 999.0,
                "min_age_unit": "Years",
                "max_age_unit": "Years",
                "max_age_in_years": 999.0,
                "gender": "BOTH",
                "accepts_healthy_volunteers": false,
                "min_age": "18 Years",
                "min_age_number": 18.0,
                "min_age_in_years": 18.0
            }
        },
        "completion_date_type_code": "ANTICIPATED",
        "detail_description": null,
        "official_title": "A Phase 1/2 Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers",
        "_phase_sort_order": 3,
        "collaborators": [],
        "associated_studies": [],
        "outcome_measures": [
            {
                "timeframe": "Approximately 5 years",
                "name": "Area under the serum concentration-time curve from time zero to time of last quantifiable concentration [AUC(0-T)]",
                "description": "Part 1 and Part 2",
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "Approximately 5 years",
                "name": "Area under the serum concentration-time curve in 1 dosing interval [AUC(TAU)]",
                "description": "Part 1 and Part 2",
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "Approximately 5 years",
                "name": "Incidence of adverse events (AE)",
                "description": "Part 1",
                "type_code": "PRIMARY"
            },
            {
                "timeframe": "Approximately 5 years",
                "name": "Incidence of AEs",
                "description": "Part 2",
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "Approximately 5 years",
                "name": "Incidence of AEs leading to discontinuation",
                "description": "Part 1",
                "type_code": "PRIMARY"
            },
            {
                "timeframe": "Approximately 5 years",
                "name": "Incidence of AEs leading to discontinuation",
                "description": "Part 2",
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "Approximately 5 years",
                "name": "Incidence of AEs meeting protocol-defined dose limiting toxicities (DLT) criteria",
                "description": "Part 1",
                "type_code": "PRIMARY"
            },
            {
                "timeframe": "Approximately 5 years",
                "name": "Incidence of anti-drug antibody (ADA) to BMS-986253",
                "description": "Part 1 and Part 2",
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "Approximately 5 years",
                "name": "Incidence of clinically significant changes in clinical laboratory results: Clinical Chemistry tests",
                "description": "Part 1",
                "type_code": "PRIMARY"
            },
            {
                "timeframe": "Approximately 5 years",
                "name": "Incidence of clinically significant changes in clinical laboratory results: Clinical Chemistry tests",
                "description": "Part 2",
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "Approximately 5 years",
                "name": "Incidence of clinically significant changes in clinical laboratory results: Hematology tests",
                "description": "Part 1",
                "type_code": "PRIMARY"
            },
            {
                "timeframe": "Approximately 5 years",
                "name": "Incidence of clinically significant changes in clinical laboratory results: Hematology tests",
                "description": "Part 2",
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "Approximately 5 years",
                "name": "Incidence of clinically significant changes in clinical laboratory results: Urinalysis tests",
                "description": "Part 1",
                "type_code": "PRIMARY"
            },
            {
                "timeframe": "Approximately 5 years",
                "name": "Incidence of clinically significant changes in clinical laboratory results: Urinalysis tests",
                "description": "Part 2",
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "Approximately 5 years",
                "name": "Incidence of death",
                "description": "Part 2",
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "Approximately 5 years",
                "name": "Incidence of deaths",
                "description": "Part 1",
                "type_code": "PRIMARY"
            },
            {
                "timeframe": "Approximately 5 years",
                "name": "Incidence of SAEs",
                "description": "Part 2",
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "Approximately 5 years",
                "name": "Incidence of serious adverse events (SAE)",
                "description": "Part 1",
                "type_code": "PRIMARY"
            },
            {
                "timeframe": "Approximately 5 years",
                "name": "Maximum observed serum concentration (Cmax)",
                "description": "Part 1 and Part 2",
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "Approximately 5 years",
                "name": "Median duration of response (mDOR) per response evaluation criteria in solid tumors (RECIST) v1.1",
                "description": "Part 1",
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "Approximately 5 years",
                "name": "Objective response rate (ORR) based on Blinded independent central review (BICR) assessments per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1",
                "description": "Part 1 and Part 2",
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "Approximately 5 years",
                "name": "Observed serum concentration at the end of a dosing interval (CTAU)",
                "description": "Part 1 and Part 2",
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "Approximately 5 years",
                "name": "Overall Survival (OS)",
                "description": "Part 2",
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "Approximately 5 years",
                "name": "Progression-free survival (PFS) hazard ratio based on Blinded independent central review (BICR) assessments per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1",
                "description": "Part 2, participants with advanced melanoma, selected by baseline serum interleukin-8 (IL-8) level using RECIST v1.1",
                "type_code": "PRIMARY"
            },
            {
                "timeframe": "Approximately 5 years",
                "name": "Progression-free survival (PFS) hazard ratio based on Blinded independent central review (BICR) assessments per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1",
                "description": "Part 2, participants with advanced melanoma, using RECIST v1.1 (regardless of baseline serum IL-8 levels)",
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "Approximately 5 years",
                "name": "Serum biomarker concentration",
                "description": "Part 1",
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "Approximately 5 years",
                "name": "Time of maximum observed serum concentration (Tmax)",
                "description": "Part 1 and Part 2",
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "Approximately 5 years",
                "name": "Trough observed serum concentration at the end of the dosing interval (CTROUGH)",
                "description": "Part 1 and Part 2",
                "type_code": "SECONDARY"
            }
        ],
        "phase": "I_II",
        "central_contact": {
            "phone": null,
            "name": null,
            "type": null,
            "email": null
        },
        "primary_purpose": "TREATMENT",
        "number_of_arms": 5,
        "_study_protocol_type_sort_order": 0,
        "nct_id": "NCT03400332",
        "biomarkers": [],
        "classification_code": null,
        "current_trial_status_date": "2021-03-10",
        "diseases": [
            {
                "inclusion_indicator": "TRIAL",
                "is_lead_disease": true,
                "synonyms": [
                    "Recurrent Solid Tumor",
                    "Relapsed Malignant Solid Neoplasm",
                    "Recurrent Malignant Solid Neoplasm",
                    "Relapsed Solid Neoplasm",
                    "Relapsed Solid Tumor",
                    "Recurrent Solid Neoplasm"
                ],
                "nci_thesaurus_concept_id": "C127153",
                "name": "Recurrent Malignant Solid Tumor",
                "type": [
                    "stage"
                ],
                "parents": [
                    "C132146",
                    "C4813"
                ]
            },
            {
                "inclusion_indicator": "TRIAL",
                "is_lead_disease": false,
                "synonyms": [
                    "Metastatic Solid Neoplasm",
                    "Metastatic Malignant Solid Neoplasm",
                    "Metastatic Solid Tumor"
                ],
                "nci_thesaurus_concept_id": "C127155",
                "name": "Metastatic Malignant Solid Tumor",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C36263",
                    "C132146"
                ]
            },
            {
                "inclusion_indicator": "TRIAL",
                "is_lead_disease": false,
                "synonyms": [
                    "Advanced Solid Tumor",
                    "Advanced Solid Neoplasm",
                    "Advanced Non-Hematologic Malignancy",
                    "Advanced Malignant Solid Neoplasm"
                ],
                "nci_thesaurus_concept_id": "C129707",
                "name": "Advanced Malignant Solid Tumor",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C9270",
                    "C127155"
                ]
            },
            {
                "inclusion_indicator": "TRIAL",
                "is_lead_disease": false,
                "synonyms": [
                    "Unresectable Malignant Solid Neoplasm"
                ],
                "nci_thesaurus_concept_id": "C148036",
                "name": "Unresectable Malignant Solid Tumor",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C127156",
                    "C27359",
                    "C132146"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Solid Neoplasm",
                    "Solid Tumour",
                    "Solid tumor, NOS"
                ],
                "nci_thesaurus_concept_id": "C9292",
                "name": "Solid Tumor",
                "type": [
                    "maintype"
                ],
                "parents": [
                    "C7062"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Neoplasm Recurrence",
                    "Recurrence",
                    "Recurrent Tumor",
                    "Recurrent"
                ],
                "nci_thesaurus_concept_id": "C4798",
                "name": "Recurrent Neoplasm",
                "type": [
                    "stage"
                ],
                "parents": [
                    "C7062"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Neoplasm",
                    "Neoplasms, NOS",
                    "tumor",
                    "Neoplastic Growth",
                    "Tumor, NOS",
                    "Neoplasia",
                    "Neoplasm, NOS",
                    "Neoplastic Disease"
                ],
                "nci_thesaurus_concept_id": "C3262",
                "name": "Other Neoplasm",
                "type": [
                    "maintype"
                ],
                "parents": [
                    "C2991"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [],
                "nci_thesaurus_concept_id": "C7062",
                "name": "Neoplasm by Special Category",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C3262"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "disease term",
                    "Diseases",
                    "Disease",
                    "Diseases and Disorders",
                    "disease_term",
                    "Diagnosis",
                    "Disease or Disorder, Non-Neoplastic",
                    "disease type",
                    "Disorders",
                    "Disease or Disorder",
                    "Disorder",
                    "condition",
                    "disease_type"
                ],
                "nci_thesaurus_concept_id": "C2991",
                "name": "Other Disease",
                "type": [
                    "maintype"
                ],
                "parents": []
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Malignant Solid Neoplasm"
                ],
                "nci_thesaurus_concept_id": "C132146",
                "name": "Malignant Solid Tumor",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C9292",
                    "C9305"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Neoplasm, malignant",
                    "Cancer",
                    "Tumor, malignant, NOS",
                    "Malignancy",
                    "Unclassified tumor, malignant",
                    "Malignant Neoplastic Disease",
                    "Malignant Growth",
                    "CA",
                    "Malignant Tumor"
                ],
                "nci_thesaurus_concept_id": "C9305",
                "name": "Malignant Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C7062"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Recurrence",
                    "Recurrent Cancer",
                    "Recurrent Malignant Tumor"
                ],
                "nci_thesaurus_concept_id": "C4813",
                "name": "Recurrent Malignant Neoplasm",
                "type": [
                    "stage"
                ],
                "parents": [
                    "C4798",
                    "C9305"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": false,
                "synonyms": [
                    "Secondary Cancer",
                    "Secondary Malignancy"
                ],
                "nci_thesaurus_concept_id": "C4968",
                "name": "Secondary Malignant Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C36255",
                    "C9305"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": false,
                "synonyms": [
                    "Unresectable Solid Neoplasm"
                ],
                "nci_thesaurus_concept_id": "C127156",
                "name": "Unresectable Solid Tumor",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C9292"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": false,
                "synonyms": [
                    "Advanced Cancer"
                ],
                "nci_thesaurus_concept_id": "C9270",
                "name": "Advanced Malignant Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C36263"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": false,
                "synonyms": [
                    "Tumor, metastatic",
                    "Metastatic Tumor",
                    "Neoplasm, metastatic",
                    "Metastatic"
                ],
                "nci_thesaurus_concept_id": "C3261",
                "name": "Metastatic Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C7062"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": false,
                "synonyms": [
                    "Secondary Tumor",
                    "Tumor, secondary",
                    "Neoplasm, secondary"
                ],
                "nci_thesaurus_concept_id": "C36255",
                "name": "Secondary Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C7062"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": false,
                "synonyms": [
                    "Metastatic Cancer"
                ],
                "nci_thesaurus_concept_id": "C36263",
                "name": "Metastatic Malignant Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C4968",
                    "C3261"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": false,
                "synonyms": [
                    "Unresectable Malignant Tumor"
                ],
                "nci_thesaurus_concept_id": "C27359",
                "name": "Unresectable Malignant Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C9305"
                ]
            }
        ],
        "_primary_purpose_sort_order": 0,
        "protocol_id": "CA027-002",
        "active_sites_count": 5,
        "lead_org_cancer_center": null,
        "arms": [
            {
                "interventions": [
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C141144",
                        "name": "Immune Checkpoint Modulator",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent category",
                        "parents": [
                            "C308"
                        ]
                    },
                    {
                        "inclusion_indicator": "TRIAL",
                        "synonyms": [
                            "Opdivo"
                        ],
                        "nci_thesaurus_concept_id": "C68814",
                        "name": "Nivolumab",
                        "description": "A fully human monoclonal antibody directed against  the  negative immunoregulatory human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1/PCD-1) with immunopotentiation activity.  Nivolumab binds to and blocks the activation of PD-1, an Ig superfamily transmembrane protein, by its ligands PD-L1 and PD-L2, resulting in the activation of T-cells and cell-mediated  immune responses against tumor cells or pathogens. Activated PD-1 negatively regulates T-cell activation and effector function through the suppression of P13k/Akt pathway activation.  Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)Health professional",
                        "type": "Biological/Vaccine",
                        "category": "agent",
                        "parents": [
                            "C129822",
                            "C128037"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C43431",
                        "name": "Activity",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": []
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C1908",
                        "name": "Drug, Food, Chemical or Biomedical Material",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent category",
                        "parents": []
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Immunotherapy Agent",
                            "Immune Mediators",
                            "Immunomodulating Agent",
                            "Immunomodulators",
                            "Immune Modulators",
                            "Immune Regulators",
                            "Immunotherapeutic Agent",
                            "Immunomodulatory Agent",
                            "BRM",
                            "Immunopotentiators",
                            "Biological Response Modifier",
                            "Biomodulators"
                        ],
                        "nci_thesaurus_concept_id": "C308",
                        "name": "Immunotherapy",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent category",
                        "parents": [
                            "C1909"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Anti-tumor Targeted Therapy Agent",
                            "Molecularly Targeted Therapy Agent",
                            "Targeted Therapeutic Agent",
                            "Targeted Agent"
                        ],
                        "nci_thesaurus_concept_id": "C163758",
                        "name": "Targeted Therapy Agent",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent category",
                        "parents": [
                            "C274"
                        ]
                    },
                    {
                        "inclusion_indicator": "TRIAL",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C124227",
                        "name": "Anti-IL-8 Monoclonal Antibody BMS-986253",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent",
                        "parents": [
                            "C129822",
                            "C20401"
                        ]
                    },
                    {
                        "inclusion_indicator": "TRIAL",
                        "synonyms": [
                            "Yervoy"
                        ],
                        "nci_thesaurus_concept_id": "C2654",
                        "name": "Ipilimumab",
                        "description": "A monoclonal antibody directed against cytotoxic T-lymphocyte-associated antigen-4 (CTLA4), an antigen that is expressed on activated T-cells and exhibits affinity for B7 co-stimulatory molecules. By binding CTLA4, ipilimumab enhances T-cell activation and blocks B7-1 and B7-2 T-cell co-stimulatory pathways. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)Health professional",
                        "type": "Biological/Vaccine",
                        "category": "agent",
                        "parents": [
                            "C129822",
                            "C128036"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Immunologic, Immunochemical",
                            "Biologics",
                            "Biologicals",
                            "Biological Products",
                            "Immunologics",
                            "Biopharmaceuticals"
                        ],
                        "nci_thesaurus_concept_id": "C307",
                        "name": "Biological Agent",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent category",
                        "parents": [
                            "C1909"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Anti-cancer Antibody",
                            "Anticancer Antibody",
                            "Antineoplastic Ab"
                        ],
                        "nci_thesaurus_concept_id": "C129822",
                        "name": "Antineoplastic Antibody",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent category",
                        "parents": [
                            "C129821"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C143250",
                        "name": "Immune Checkpoint Inhibitor",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent category",
                        "parents": [
                            "C141144"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Anti-Tumor Drugs",
                            "Chemotherapeutic Agents, Neoplastic Disease",
                            "Anti-Cancer Agents",
                            "Antiproliferative Drugs",
                            "Anti-Tumor Agents",
                            "Antineoplastic Drugs",
                            "Tumor-Specific Treatment Agents",
                            "Antineoplastics",
                            "Antiproliferative Agents",
                            "Cancer Drug"
                        ],
                        "nci_thesaurus_concept_id": "C274",
                        "name": "Antineoplastic Agent",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent category",
                        "parents": [
                            "C1909"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C16203",
                        "name": "Clinical or Research Activity",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C43431"
                        ]
                    },
                    {
                        "inclusion_indicator": "TRIAL",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C116558",
                        "name": "Placebo Administration",
                        "description": null,
                        "type": "Drug",
                        "category": "agent",
                        "parents": [
                            "C49236"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Intervention Strategies",
                            "Intervention",
                            "Procedure"
                        ],
                        "nci_thesaurus_concept_id": "C25218",
                        "name": "Intervention or Procedure",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C16203"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Monoclonal Antibody",
                            "Monoclonal Antibodies"
                        ],
                        "nci_thesaurus_concept_id": "C20401",
                        "name": "Monoclonal Antibody Therapy",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent category",
                        "parents": [
                            "C308",
                            "C307"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C191738",
                        "name": "CTLA-4-targeting Agent",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent category",
                        "parents": [
                            "C141144",
                            "C163758"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Antineoplastic Biotherapeutic",
                            "Anticancer Biological",
                            "Anti-cancer Biological Agent",
                            "Antineoplastic Biological"
                        ],
                        "nci_thesaurus_concept_id": "C129821",
                        "name": "Antineoplastic Biological Agent",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent category",
                        "parents": [
                            "C274",
                            "C307"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "PD-1 Inhibitor",
                            "Protein PD-1 Inhibitor",
                            "Anti-PD-1 Agent",
                            "Programmed Cell Death Protein 1 Inhibitor",
                            "PD-1-targeting Agent"
                        ],
                        "nci_thesaurus_concept_id": "C124946",
                        "name": "PD1 Inhibitor",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent category",
                        "parents": [
                            "C163758",
                            "C143250"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Anti-PD-1 Monoclonal Antibody"
                        ],
                        "nci_thesaurus_concept_id": "C128037",
                        "name": "Anti-PD1 Monoclonal Antibody",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent category",
                        "parents": [
                            "C124946",
                            "C20401"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Therapeutic Interventions",
                            "Therapy",
                            "Therapeutic Technique",
                            "Therapeutic Method"
                        ],
                        "nci_thesaurus_concept_id": "C49236",
                        "name": "Therapeutic Procedure",
                        "description": null,
                        "type": "Drug",
                        "category": "agent category",
                        "parents": [
                            "C25218"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Pharmaceutical Agent",
                            "Drug Substance",
                            "Pharmaceuticals",
                            "Pharmacological Substance",
                            "Agent",
                            "Drug",
                            "Pharmacologic Agent"
                        ],
                        "nci_thesaurus_concept_id": "C1909",
                        "name": "Pharmacologic Substance",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent category",
                        "parents": [
                            "C1908"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Anti-CTLA4 Monoclonal Antibody"
                        ],
                        "nci_thesaurus_concept_id": "C128036",
                        "name": "Anti-CTLA-4 Monoclonal Antibody",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent category",
                        "parents": [
                            "C191738",
                            "C20401"
                        ]
                    }
                ],
                "name": "Arm not specified",
                "description": null,
                "type": null
            },
            {
                "interventions": [],
                "name": "Part 1A: BMS-986253 + nivolumab",
                "description": null,
                "type": "EXPERIMENTAL"
            },
            {
                "interventions": [],
                "name": "Part 1B: BMS-986253 + nivolumab",
                "description": null,
                "type": "EXPERIMENTAL"
            },
            {
                "interventions": [],
                "name": "Part 1C: BMS-986253 + nivolumab + ipilimumab",
                "description": null,
                "type": "EXPERIMENTAL"
            },
            {
                "interventions": [],
                "name": "Part 2A: BMS-986253 + nivolumab + ipilimumab",
                "description": null,
                "type": "EXPERIMENTAL"
            },
            {
                "interventions": [],
                "name": "Part 2B: Placebo + nivolumab + ipilimumab",
                "description": null,
                "type": "PLACEBO_COMPARATOR"
            }
        ],
        "study_model_code": null,
        "nci_id": "NCI-2018-00525",
        "why_study_stopped": null,
        "brief_summary": "The purpose of this study is to investigate experimental medication BMS-986253 in combination\r\n      with Nivolumab or Nivolumab plus Ipilimumab in participants with advanced cancers.",
        "brief_title": "A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers",
        "status_history": [
            {
                "status_date": "2021-03-10T00:00:00.000002",
                "status": "ACTIVE"
            },
            {
                "status_date": "2020-06-19T00:00:00.000001",
                "status": "TEMPORARILY_CLOSED_TO_ACCRUAL"
            },
            {
                "status_date": "2018-01-31T00:00:00",
                "status": "ACTIVE"
            }
        ],
        "study_population_description": null,
        "sampling_method_code": null,
        "minimum_target_accrual_number": 372,
        "prior_therapy": [],
        "_current_trial_status_sort_order": 0,
        "start_date": "2018-02-12",
        "record_verification_date": "2023-02-01",
        "ctep_id": null,
        "current_trial_status": "Active",
        "study_model_other_text": null,
        "masking": {
            "role_caregiver": null,
            "masking": null,
            "role_investigator": null,
            "role_outcome_assessor": null,
            "role_subject": null,
            "allocation_code": "Randomized Controlled Trial"
        },
        "acronym": null,
        "nci_programs": [],
        "nci_funded": "Indirect",
        "anatomic_sites": [
            "Multiple"
        ],
        "ccr_id": null,
        "start_date_type_code": "ACTUAL",
        "principal_investigator": null,
        "study_source": "Industrial",
        "completion_date": "2025-11-30",
        "study_subtype_code": null,
        "study_protocol_type": "Interventional"
    }
]